For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the maximum percentage of net profit shared on sales of the product.

+ References

No definition available.

+ Details

Name:	vrx_BusinessCombinationPercentageOfProfitSharingMaximum
Namespace Prefix:	vrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the maximum percentage of royalty payments associated with net commercial sales of products based on backup compounds.

+ References

No definition available.

+ Details

Name:	vrx_BusinessCombinationPercentageOfRoyaltyRatePaymentsForProductBasedOnBackupCompoundsMaximum
Namespace Prefix:	vrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the maximum percentage of royalty payments associated with net commercial sales of the product outside of the Collaboration Territory.

+ References

No definition available.

+ Details

Name:	vrx_BusinessCombinationPercentageOfRoyaltyRatePaymentsMaximumOutsideOfCollaborationTerritory
Namespace Prefix:	vrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the amount of consideration paid for the rights under the collaboration and option agreements.

+ References

No definition available.

+ Details

Name:	vrx_CollaborationAgreementConsiderationPaid
Namespace Prefix:	vrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the term of rights under the collaboration and option agreements.

+ References

No definition available.

+ Details

Name:	vrx_CollaborationAgreementTermOfRights
Namespace Prefix:	vrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement.

+ References

No definition available.

+ Details

Name:	vrx_CollaborativeAgreementMilestonePaymentsAggregate
Namespace Prefix:	vrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the milestone payment to be received contingent upon the first sale of a product under a collaborative agreement.

+ References

No definition available.

+ Details

Name:	vrx_CollaborativeAgreementMilestonePaymentToBeReceivedContingentUponFirstSale
Namespace Prefix:	vrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

COLLABORATION AGREEMENTS (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended	3 Months Ended					1 Months Ended			0 Months Ended	3 Months Ended
	Dec. 31, 2013 Ezogabine Retigabine	Sep. 30, 2013 Non-recurring basis Ezogabine Retigabine Amortization and Impairments of Finite-lived Intangible Assets	Sep. 30, 2013 Non-recurring basis Ezogabine Retigabine In-process Research and Development Impairments and Other Charges	Dec. 31, 2013 Living Proof, Inc. Neotensil Maximum	Dec. 31, 2013 SMG Bensal, HP Maximum	Mar. 31, 2010 NicOx Latanoprostene Bunod Maximum	Jul. 31, 2013 Mimetogen MIM-D3 compound Maximum	Mar. 30, 2012 Collaborations Medicis	Mar. 30, 2012 Collaborations Development and license agreement with a specialty pharmaceutical company	Oct. 02, 2012 BMS Collaboration and Option Agreement	Dec. 31, 2012 BMS Collaboration and Option Agreement	Oct. 31, 2008 GSK Ezogabine/retigabine	May 31, 2011 GSK TrobaltTM	Apr. 30, 2012 GSK PotigaTM
Collaboration Agreement
Consideration paid for rights				$ 15.0	$ 5.0		$ 95.0				$ 83.3
Milestone payments in terms of collaboration and license agreements				62.5	80.0	162.5	345.0
Term of additional rights										2 years
Potential contingent consideration payment								80.0	120.0
GSK milestone payment, maximum percentage of royalty on net sales of product outside of the Collaboration Territory												20.00%	20.00%
GSK milestone payment, maximum percentage of royalty on net sales of backup compounds												20.00%
GSK milestone payment													40.0	45.0
GSK milestone payment, maximum percentage of net profits shared on sales of product														50.00%
Impairment charges	$ 551.6	$ 551.6	$ 93.8